Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PPAR alpha · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| PPAR alpha | DRUG | - |
| Hydrochlorothiazide | DRUG | - |
| Placebo | DRUG | - |
| atorvastatin | DRUG | - |
Inclusion Criteria: 1. Are men and women between 18 and 70 years of age, inclusive 2. Have given signed informed consent to participate in this study 3. Are diagnosed with mild essential hypertension at screening (currently untreated or treated with monotherapy) Exclusion Criteria: 1. Secondary o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 2 | PHASE3 | Lepodisiran |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide, Rosuvastatin |
| NewAmsterdam Pharma Company N.V. | NAMS | 3 | PHASE3 | obicetrapib, ezetimibe daily |
| AstraZeneca PLC | AZN | 3 | PHASE2 | AZD0780, Rosuvastatin |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE1 | ARO-DIMERPA |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX310 |
| HeartFlow, Inc. | HTFL | 1 | N/A | Rosuvastatin |
PPAR alpha is an investigational small molecule being developed by Eli Lilly and Company for cardiovascular conditions, including dyslipidemia, mild hypertension, and hypercholesterolemia. It is currently in Phase 2 clinical development and is not yet approved by the FDA.
PPAR alpha is a small molecule that targets the PPAR alpha receptor, a nuclear receptor involved in lipid metabolism. By activating this receptor, it is intended to address abnormal fat levels in the blood and related cardiovascular conditions.
PPAR alpha is being developed by Eli Lilly and Company, a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 2 clinical trials for cardiovascular indications.
PPAR alpha is in Phase 2 clinical development. It has completed three Phase 2 trials, and it remains an investigational drug, meaning it has not received FDA approval and is still being studied for safety and efficacy.
PPAR alpha has completed three Phase 2 clinical trials: NCT00116519 in dyslipidemia, NCT00133380 in hypercholesterolemia, and NCT00374855 in mild hypertension. These trials were conducted in the United States and Sweden, with enrollment ranging from 153 to 300 participants.
PPAR alpha is not known by any alternative names. It is a distinct investigational compound developed by Eli Lilly and Company, and no other names for this drug have been reported.